Protein tyrosine phosphatase non-receptor type 7 (PTPN7)

Protein tyrosine phosphatase non-receptor type 7 (PTPN7, also known as HePTP, LC-PTP) is a member of the non-receptor PTP family, functioning as a phosphatase that tightly controls immune cell activation and signaling. It is highly expressed in hematopoietic cells, particularly T lymphocytes and macrophages, serving as a negative regulator of MAPK pathways by dephosphorylating and inactivating ERK, p38, and JNK. Elevated PTPN7 expression has been observed in various malignancies, including glioma, breast, lung, bladder, and melanoma, and is associated with poor prognosis and higher tumor grade. PTPN7 expression is closely linked to immune cell infiltration (notably T cells and macrophages) and immune checkpoint marker expression (PD-L1, CTLA-4), making it a promising biomarker for immunotherapy response. While direct therapeutic agents targeting PTPN7 remain under research, its role as a molecular modulator of immune response positions it as a novel candidate in cancer immunotherapy and as a prognostic biomarker in multiple tumor types.

Other names

Hematopoietic protein-tyrosine phosphataseHePTPLC-PTPBPTP-4LPTPPTPNIDual specificity phosphatase 1

For immune checkpoint blockade (ICB): PTPN7 serves as a biomarker for predicting better response to PD-1/PD-L1 and CTLA-4 inhibitors and may regulate immune microenvironment sensitivity to these drugs. As a phosphatase: Dephosphorylates and inactivates MAPK signaling in T cells and macrophages, leading to negative regulation of their activation.